Featuring articles on amino acid infusion and kidney protection, azithromycin to reduce childhood mortality in Niger, belzutifan in renal-cell carcinoma, and a transfusion strategy in traumatic brain injury; a review article on sexual dysfunction in women; a case report of a woman with aphasia, anemia, and a breast mass; and Perspectives on a series of brief ... Show More
Aug 20
NEJM This Week — August 21, 2025
Featuring articles on lung cancer, vasomotor symptoms in breast cancer, autoimmune pulmonary alveolar proteinosis, and high-risk cutaneous squamous-cell carcinoma; a review article on educational strategies for clinical supervision of AI use; a case report of a woman with fatigue ... Show More
23m 14s
Aug 6
NEJM This Week — August 7, 2025
Featuring articles on treatments for chronic kidney disease and type 2 diabetes, bubonic plague, and advanced breast cancer; a review article on hypogonadism; a Clinical Problem-Solving describing gasping for strength; a Medicine and Society on the infant mortality rate; and Pers ... Show More
23m 13s
Jul 24
A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse
In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After t ... Show More
18m 51s
Apr 2022
Structural racism and AML survival, promoter competition and hemoglobin switching, and CAR T-cell therapy and high-risk cytogenetics in ALL
In this week’s episode we’ll first cover a research article demonstrating the striking contribution of neighborhood disadvantage to racial and ethnic disparities in survival in patients with acute myeloid leukemia. The second research article provides a model for understanding ho ... Show More
17m 55s
Nov 2024
JACC - November 26, 2024 Issue Summary
In the November 26, 2024 issue of JACC, Dr. Valentin Fuster highlights four pivotal studies in cardiovascular research. The first explores the independent roles of social determinants of health and polygenic risk scores in coronary heart disease, while the second assesses the imp ... Show More
25m 7s
Jul 2024
Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ... Show More
56m 23s
Dec 2024
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show More
20m 5s
Nov 2024
First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia
In this week's episode we’ll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD g ... Show More
21m 19s
Apr 2024
JVS CIT Editorials and Abstracts - April 2024
In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by members of our SVS Social Media Ambassadors and Editor in Chief of JVS CIT, Dr. Matthew Smeds. Readers: ... Show More
30m 57s
May 8
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesios ... Show More
19m 58s